Monopar Therapeutics (NASDAQ:MNPR) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly earnings of ($0.48) per share, missing analysts' estimates by $0.02. The stock price fell $9.00 to $78.01. Analysts have mixed ratings, with some upgrading to 'strong-buy' and others downgrading. Major shareholder Tactic Pharma sold 550,229 shares. Institutional investors have made recent changes to their positions. Monopar's lead product, Validive, is in Phase 2b/3 trials for cancer treatment.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.02), Zacks reports.

Get Monopar Therapeutics alerts:

Monopar Therapeutics Price Performance

Shares of NASDAQ MNPR traded down $9.00 during trading hours on Friday, hitting $78.01. 123,249 shares of the stock were exchanged, compared to its average volume of 54,107. Monopar Therapeutics has a one year low of $17.09 and a one year high of $105.00. The company's 50 day moving average is $77.45 and its 200 day moving average is $51.16. The firm has a market capitalization of $481.32 million, a P/E ratio of -23.22 and a beta of 1.35.

Wall Street Analyst Weigh In

MNPR has been the topic of a number of research reports. Jones Trading upgraded Monopar Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Friday, October 10th. Raymond James Financial cut shares of Monopar Therapeutics from a "strong-buy" rating to an "outperform" rating and lowered their price target for the company from $142.00 to $123.00 in a report on Friday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Wednesday, October 8th. BTIG Research lifted their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the company a "buy" rating in a research report on Thursday, September 25th. Finally, Barclays set a $125.00 target price on Monopar Therapeutics and gave the stock an "overweight" rating in a research report on Monday, October 13th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Monopar Therapeutics currently has a consensus rating of "Buy" and an average price target of $106.20.

Read Our Latest Analysis on MNPR

Insiders Place Their Bets

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the company's stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the completion of the sale, the insider directly owned 272,026 shares in the company, valued at $17,303,573.86. This represents a 66.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MNPR. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets grew its holdings in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock worth $57,000 after purchasing an additional 349 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Monopar Therapeutics during the 2nd quarter worth about $80,000. Finally, New York State Common Retirement Fund acquired a new position in Monopar Therapeutics in the second quarter valued at about $104,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Should You Invest $1,000 in Monopar Therapeutics Right Now?

Before you consider Monopar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.

While Monopar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here